J 2021

Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis

DASTYCH, Milan, Libuse HUSOVA, Kvetoslava AIGLOVA, Tomas FEJFAR, Milan DASTYCH et. al.

Základní údaje

Originální název

Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis

Autoři

DASTYCH, Milan (203 Česká republika, garant), Libuse HUSOVA (203 Česká republika), Kvetoslava AIGLOVA (203 Česká republika), Tomas FEJFAR (203 Česká republika) a Milan DASTYCH (203 Česká republika, domácí)

Vydání

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, ABINGDON, INFORMA HEALTHCARE, 2021, 0036-5513

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.209

Kód RIV

RIV/00216224:14110/21:00121702

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000607121500001

Klíčová slova anglicky

Manganese; copper; cholestasis; primary biliary cirrhosis; primary sclerosing cholangitis

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 3. 6. 2021 08:06, Mgr. Tereza Miškechová

Anotace

V originále

The liver and the biliary tree form the main excretory route of manganese (Mn) and copper (Cu). Cholestasis, can lead to the accumulation of these trace elements in the organism, resulting in toxicity to the basal ganglia of the central nervous system. The aim of our study was to reveal the influence of long-term cholestasis on the Mn and Cu levels in the blood of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). We recruited patients with PBC (n = 20) and PSC (n = 32). A control group (n = 40) was also set up. We also examined serum bile acid concentrations and liver enzyme activities. We did not observe any significant differences in any of these parameters between the PBC and PSC groups. The Mn and Cu levels in the PBC and PSC patients differed significantly from the that in the control group (p < 0.0001 and p < .021, respectively). Patients in whom the laboratory cholestasis markers normalized during ursodeoxycholic acid treatment (18/52;35%) presented with significantly lower levels of Mn and Cu (p = .015 and p = .012, respectively). Ten PSC patients showed normal levels of Mn and Cu six months after liver transplantation. Fine tremors, rigidity, dysarthria, and hypomimia were reported in nine (23%), eight (20%), four (10%), and eight (20%) patients, respectively. In addition to monitoring the cholestasis levels, liver function, and Mn and Cu levels during the long-term treatment of PBC and PSC patients, it is important to also regularly monitor the occurrence and development of extrapyramidal symptoms of Parkinson's-like syndromes.